Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens

<p>Abstract</p> <p>Background</p> <p>After the introduction of novel effective immunosuppressive therapies, kidney transplantation became the treatment of choice for end stage renal disease. While these new therapies lead to better graft survival, they can also cause a...

Full description

Bibliographic Details
Main Authors: Kirby Sean, Satoskar Anjali, Brodsky Sergey, Pope-Harman Amy, Nunley David, Hitchcock Charles, Pelletier Ronald, Ross Patrick, Nadasdy Tibor, Shilo Konstantin
Format: Article
Language:English
Published: BMC 2012-03-01
Series:Diagnostic Pathology
Subjects:
Online Access:http://www.diagnosticpathology.org/content/7/1/25
id doaj-2a6291557ffd459b8f8ef713bde40609
record_format Article
spelling doaj-2a6291557ffd459b8f8ef713bde406092020-11-24T21:40:24ZengBMCDiagnostic Pathology1746-15962012-03-01712510.1186/1746-1596-7-25Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimensKirby SeanSatoskar AnjaliBrodsky SergeyPope-Harman AmyNunley DavidHitchcock CharlesPelletier RonaldRoss PatrickNadasdy TiborShilo Konstantin<p>Abstract</p> <p>Background</p> <p>After the introduction of novel effective immunosuppressive therapies, kidney transplantation became the treatment of choice for end stage renal disease. While these new therapies lead to better graft survival, they can also cause a variety of complications. Only small series or case reports describe pulmonary pathology in renal allograft recipients on mTOR inhibitor inclusive therapies. The goal of this study was to provide a systematic review of thoracic biopsies in kidney transplant recipients for possible association between a type of immunosuppressive regimen and pulmonary complications.</p> <p>Methods</p> <p>A laboratory database search revealed 28 of 2140 renal allograft recipients (18 males and 10 females, 25 to 77 years old, mean age 53 years) who required a biopsy for respiratory symptoms. The histological features were correlated with clinical findings including immunosuppressive medications.</p> <p>Results</p> <p>The incidence of neoplasia on lung biopsy was 0.4% (9 cases), which included 3 squamous cell carcinomas, 2 adenocarcinomas, 1 diffuse large B-cell lymphoma, 1 lymphomatoid granulomatosis, and 2 post transplant B-cell lymphoproliferative disorders. Diffuse parenchymal lung disease was identified in 0.4% (9 cases), and included 5 cases of pulmonary hemorrhage, 3 cases of organizing pneumonia and 1 case of pulmonary alveolar proteinosis. Five (0.2%) cases showed histological features indicative of a localized infectious process. Patients on sirolimus had neoplasia less frequently than patients on other immunosuppressive combinations (12.5% vs. 58.3%, <it>p </it>= 0.03). Lung biopsies in 4 of 5 patients with clinically suspected sirolimus toxicity revealed pulmonary hemorrhage as the sole histological finding or in combination with other patterns.</p> <p>Conclusions</p> <p>Our study documents a spectrum of neoplastic and non-neoplastic lesions in renal allograft recipients on current immunosuppressive therapies. Sirolimus inclusive regimens are associated with increased risk of pulmonary toxicity but may be beneficial in cases of posttransplant neoplasia.</p> <p>Virtual Slides</p> <p>The virtual slide(s) for this article can be found here: <url>http://www.diagnosticpathology.diagnomx.eu/vs/3320012126569395</url>.</p> http://www.diagnosticpathology.org/content/7/1/25Kidney transplantationPulmonary neoplasiaPulmonary hemorrhageMammalian target of rapamycin (mTOR) inhibitorsSirolimus
collection DOAJ
language English
format Article
sources DOAJ
author Kirby Sean
Satoskar Anjali
Brodsky Sergey
Pope-Harman Amy
Nunley David
Hitchcock Charles
Pelletier Ronald
Ross Patrick
Nadasdy Tibor
Shilo Konstantin
spellingShingle Kirby Sean
Satoskar Anjali
Brodsky Sergey
Pope-Harman Amy
Nunley David
Hitchcock Charles
Pelletier Ronald
Ross Patrick
Nadasdy Tibor
Shilo Konstantin
Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens
Diagnostic Pathology
Kidney transplantation
Pulmonary neoplasia
Pulmonary hemorrhage
Mammalian target of rapamycin (mTOR) inhibitors
Sirolimus
author_facet Kirby Sean
Satoskar Anjali
Brodsky Sergey
Pope-Harman Amy
Nunley David
Hitchcock Charles
Pelletier Ronald
Ross Patrick
Nadasdy Tibor
Shilo Konstantin
author_sort Kirby Sean
title Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens
title_short Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens
title_full Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens
title_fullStr Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens
title_full_unstemmed Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens
title_sort histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens
publisher BMC
series Diagnostic Pathology
issn 1746-1596
publishDate 2012-03-01
description <p>Abstract</p> <p>Background</p> <p>After the introduction of novel effective immunosuppressive therapies, kidney transplantation became the treatment of choice for end stage renal disease. While these new therapies lead to better graft survival, they can also cause a variety of complications. Only small series or case reports describe pulmonary pathology in renal allograft recipients on mTOR inhibitor inclusive therapies. The goal of this study was to provide a systematic review of thoracic biopsies in kidney transplant recipients for possible association between a type of immunosuppressive regimen and pulmonary complications.</p> <p>Methods</p> <p>A laboratory database search revealed 28 of 2140 renal allograft recipients (18 males and 10 females, 25 to 77 years old, mean age 53 years) who required a biopsy for respiratory symptoms. The histological features were correlated with clinical findings including immunosuppressive medications.</p> <p>Results</p> <p>The incidence of neoplasia on lung biopsy was 0.4% (9 cases), which included 3 squamous cell carcinomas, 2 adenocarcinomas, 1 diffuse large B-cell lymphoma, 1 lymphomatoid granulomatosis, and 2 post transplant B-cell lymphoproliferative disorders. Diffuse parenchymal lung disease was identified in 0.4% (9 cases), and included 5 cases of pulmonary hemorrhage, 3 cases of organizing pneumonia and 1 case of pulmonary alveolar proteinosis. Five (0.2%) cases showed histological features indicative of a localized infectious process. Patients on sirolimus had neoplasia less frequently than patients on other immunosuppressive combinations (12.5% vs. 58.3%, <it>p </it>= 0.03). Lung biopsies in 4 of 5 patients with clinically suspected sirolimus toxicity revealed pulmonary hemorrhage as the sole histological finding or in combination with other patterns.</p> <p>Conclusions</p> <p>Our study documents a spectrum of neoplastic and non-neoplastic lesions in renal allograft recipients on current immunosuppressive therapies. Sirolimus inclusive regimens are associated with increased risk of pulmonary toxicity but may be beneficial in cases of posttransplant neoplasia.</p> <p>Virtual Slides</p> <p>The virtual slide(s) for this article can be found here: <url>http://www.diagnosticpathology.diagnomx.eu/vs/3320012126569395</url>.</p>
topic Kidney transplantation
Pulmonary neoplasia
Pulmonary hemorrhage
Mammalian target of rapamycin (mTOR) inhibitors
Sirolimus
url http://www.diagnosticpathology.org/content/7/1/25
work_keys_str_mv AT kirbysean histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens
AT satoskaranjali histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens
AT brodskysergey histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens
AT popeharmanamy histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens
AT nunleydavid histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens
AT hitchcockcharles histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens
AT pelletierronald histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens
AT rosspatrick histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens
AT nadasdytibor histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens
AT shilokonstantin histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens
_version_ 1725926087546896384